πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11938124

Combination therapy for treatment of cancer

PMV PHARMACEUTICALS, INC. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939596

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11925664

Intracellular genomic transplant and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11925663

Methods of managing tumor flare in adoptive immunotherapy

Atara Biotherapeutics, Inc. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11926824

miRNA biogenesis in exosomes for diagnosis and therapy

The Board of Regents of the University of Texas System Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11925642

Regulation of eIF4E activity for migraine therapy

The Board of Regents of the University of Texas System Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11920132

Oligonucleotide therapy for Leber congenital amaurosis

ProQR Therapeutics II B.V. Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11919937

T cell receptors for immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11918660

Viral vectors for cancer therapy

Krystal Biotech, Inc. Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903966

Intracellular genomic transplant and methods of therapy

Regents of the University of Minnesota Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11898180

Compositions and methods for amino acid depletion therapy

Avalon Polytom (HK) Limited Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11878049

Mitapivat therapy and modulators of cytochrome P450

Agios Pharmaceuticals, Inc. Β· Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866742

Fusion proteins comprising enzyme replacement therapy enzymes

DENALI THERAPEUTICS INC. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866515

Hemiasterlin derivatives for conjugation and therapy

Sutro Biopharma, Inc. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11865122

Estrogen therapy for brain gray matter atrophy and associated disability

The Regents of the University of California Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11865186

Gene therapy treatment of atrial fibrillation

Northwestern University Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866688

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses o

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11857528

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11850226

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11850227

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11850228

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11839599

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11839598

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11819516

Immunotherapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted